Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in chinese elderly hypertensive patients with or without non-lnsulin-dependent diabetes mellitus

American Journal of Nephrology

Volumn 17, Issue 1, 1997, Pages 72-80

  Chan, Juliana C N ^a   Critchley, Julian A J H ^a   Tomlinson, Brian ^a   Chan, Thomas Y K ^a   Cockram, Clive S ^b  

^a Division of Clinical Pharmacology   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Albuminuria; Chinese elderly hypertensive patients; Felodipine; Losartan; Non insulin dependent diabetes mellitus

Indexed keywords

ALBUMIN; ANGIOTENSIN II ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; FELODIPINE; LOSARTAN POTASSIUM; SODIUM; TRIACYLGLYCEROL;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FELODIPINE; FEMALE; HONG KONG; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031055205     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169075     Document Type: Article

References (43)

1. Damsgaard EM, Fraland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990;300:297-300.
2. Viberti GC, Hill RD, Jarrett PJ, Argyropoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982:i: 1430-1432.
3. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturi-ty-onsel diabetes. N Engl J Med 1984:310:356-360.
4. Winocour PH: Microalbuminuria: Worth screening for in early-morning urine samples in diabetic, hypertensive and elderly patients. BMJ 1992:304:1196-1197.
5. Chan JCN, Cheung CK, Cheung MYF, Swami-nathan R, Critchley JAJH, Cockram CS: Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with N1DDM. Diabetes Care 1995:18:1013-1014.
6. Fyhrquist F: Clinical pharmacology of the ACE inhibitors. Drugs 1986;32(suppl 5):33-39.
7. Dahlof B: The importance of the renin-angio-tensin system in reversal of left ventricular hypertrophy. J Hypertens 1993; 11 (suppl):29- 35.
8. Pfeffer MA, Braunwald E, Moye LA, et al: on behalf of the SAVE Investigators: Effect ofcap-topril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of The Survival and Ventricular Enlargement Trial. N Engl J Med 1992:327:669-677.
9. Björck S, Mulcc H, Johnson SA, Norden G, Aurell M: Renal protective effect ofenalapril in diabetic nephropathy. BMJ 1992:304:339-343.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993:329:1456-1462.
11. Timmermans PB, Smith RD: Angiotensin II receptor subtypes: Selective antagonists and functional correlates. Eur Heart J 1994; 15(suppl D):79-87.
12. Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, fclodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-795.
13. Ganscvoort RT, de Zeeuw D, Shahinfar S, Redtield A, dc Jong PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12(suppl):37-42.
14. Remuzzi A, Perico N, Amuchastegui CS, Mal-anchini B, Battaglia C, et al: Short- and longterm effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-49.
15. Veterans Administration Co-Operative Study on Antihypertensive Agents: Racial differences in response to low dose Captopril. Br J Clin Pharmacol 1982:14:975-979.
16. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ: Racial differences in drug response: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared to American whites. N Engl J Med 1989;320:565-570.
17. Kasiskc BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993:118: 129-138.
18. Chan JCN, Critchley JAJH, Lappe JT, Raskin SJ, Suavely D, Goldberg AI: A randomized, double-blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared to fclodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995;9:765-771.
19. MacDonald D, Pang CP, Cockram CS, Swami-nathan R: Fructosamine measurement in serum and plasma. Clin Chim Acta 1987:168: 247-252.
20. Cheung CK, Swaminathan R: Rapid, economical immunolurbidimetric method of albuminuria. Clin Chem 1987:33:204-205.
21. Anderson R, Renke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
22. Scharschmidt L, Douglas J, Dunn MJ: Angiotensin II and eicosanoids in the control of glomerular size in the rat and human. Am J Physiol 1986;250:F34S-F346.
23. Singhal PC, Santiago A, Satriano J, Hays RM, Schlöndorff D: Effects of vasoactive agents on uptake of immunoglobulin G complexes by mesangial cells. Am J Physiol 1990;258:F589-F596.
24. Ritter JM, Cockcroft JR, Sciberras DG, Goldberg MR: Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature. J Hypertens 1993; 11(suppl 3):59-61.
25. Johnston CI, Vasley D, van Leeuwen BH: Role of the kallikrcin-kinin system in renal blood flow regulation. N Z Med J 1983;96:865-867.
26. Ganscvoort RT, de Zeeuw D, de Jong PE: Is the antiprotcinuric effect of ACE inhibition mediated by interference in the renin-angiotcn-sin system? Kidney lnt 1994;45:861-867.
27. Chan JCN, Nicholls MG, Cheung CK, Law LK, Swaminathan R, Cockram CS: Factors determining the blood pressure response to enala-pril and nifedipine in hypertension associated with N1DDM. Diabetes Care 1995:18:1001-1006.
28. Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ 1992:305:981-985.
29. Cody RJ: The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994; 47:586-598.
30. Meredith PA, Donnelly R, Elliott HL, Howie CA, Reid JL: Prediction of antihypertensive response to enalapril. J Hypertens 1990;8: 1085-1090.
31. Fabris B, Jackson B, Johnston CI: Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 1991:17:497-503.
32. Weidmann P, Ferrari P: Central role of sodium in hypertension in diabetic subjects. Diabetes Care 1991;14:220-232.
33. Hoelscher D, Bakris G: Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol 1994;23(suppl 1):34-38.
34. Bumicr M, Rulschmann B, Nussbcrger J, et al: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:239-247.
35. Todd PA, Faulds D: Fclodipine: A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992:44:251-277.
36. Erlcy CM, Bader B, Scheu M, et al: Renal hae-modynamics in essential hypertensives treated with losartan. Clin Nephrol 1995:43(suppi 1): 8-11.
37. Lithell HOL: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;40:203-209.
38. Chan JCN, Yeung VTF, Leung DHY, Tomlinson B, Nicholls MG, Cockram CS: The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in N1DDM. Diabetes Care 1994;17:859-862.
39. O'HoIlaren MT, Porter M: Angiotensin converting enzyme inhibitors and the allergist. Ann Allergey 1990;64:503-506.
40. Yco WW, Ramsay LE: Persistent dry cough with enalapril: Incidence depends on method used. J Hum Hypertcns 1990:4:517-520.
41. Chan WK, Chan TYK, Luk WK, Leung VKS, Li TH, Critchley JAJH: A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993;44:299-300.
42. Woo KS, Nicholls MG: High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995;40:141-144.
43. Lacourciere Y, Brunner H, Irwin R, Karlbcrg BE, Ramsay LE, Snavely DB, et al. for the Losartan Cough Study Group: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994:12:1387-1393.